ClinicalTrials.gg
TerminatedNCT01606111CAPTAINUpdated Feb 25, 2020

The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery

A Phase 4 interventional study of Cerebrolysin and 0.9% NaCl, saline in Traumatic Brain Injury, sponsored by Ever Neuro Pharma GmbH. Terminated at 1 site in Hong Kong. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by Ever Neuro Pharma GmbH · Phase 4, Interventional, and Treatment

Why this study was terminated
Poor patient recruitment
Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this trial is to investigate safety and efficacy of Cerebrolysin as add-on therapy to standard care in patients with acute traumatic brain injury (TBI). The study duration for each patient is 180 days.

02

Conditions studied

  • Traumatic Brain Injury
03

In context

Brain Injuries, Traumatic

1,721 studies on the registry are indexed under Brain Injuries, Traumatic; 447 are open to participants now.

This study's enrollment of 46 is below the median of 52 across 1,088 interventional studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Ever Neuro Pharma GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of TBI and a GCS 7-12
  • Only isolated TBI
  • CT
  • Pre-Trauma -Index = 100
  • Age 18-60 years
  • Male and female patients
  • Time to needle for study medication within 6 hours after injury
  • Patient is not pregnant or lactating during the trial and is not of
  • Patient was able to speak, read and write in a pre-defined study language before the accident.
  • Reasonable expectation of completion of outcome measures at follow-up
  • Written

Exclusion criteria

Exclusion Criteria:

  • Evidence of pre-existing major health problems
  • Any neurological or non-neurological condition independent from TBI that might influence the functional outcome or other efficacy outcome measures
  • Injury of writing hand influencing cognitive or other outcome measures
  • Clear clinical signs of intoxication influencing the evaluation
  • Major drug dependency including alcohol
  • Chronic treatment with , Ca2+-channel blockers or major anticoagulants
  • Penetrating high-velocity missile head trauma
  • Stab wound trauma into the brain
  • Patients with spinal cord injury
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Placebo comparator
    0.9% NaCl, saline

    Drug: 0.9% NaCl, saline

  • Experimental
    Cerebrolysin

    Drug: Cerebrolysin

Interventions

  • IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)

    Also known as: Cognicer, Renacenz

  • Drug0.9% NaCl, saline

    IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Composite endpoint of mean score in MMSE, PSI, Stroop Color-Word Test, Early Reha BI, GOS-E

    Global status is assessed by an ensemble of appropriate, single efficacy criteria to be tested by a multivariate, directional test approach

    Time frame: Day 10

  2. Composite endpoint of mean score in PSI, Stroop Color-Word Test, Color Trails Test, Digit Span, Early Reha BI, Finger Tapping Test, MMSE, Hospital Anxiety and Depression Scale, GOS-E

    Time frame: Day 30

  3. Composite endpoint of mean score in PSI, Stroop Color-Word Test, Color Trails Test, Digit Span, Early Reha BI, Finger Tapping Test, MMSE, Hospital Anxiety and Depression Scale, GOS-E

    Time frame: Day 90

Secondary outcomes

  1. Mortality

    Time frame: Day 10

  2. Mortality

    Time frame: Day 30

  3. Mortality

    Time frame: Day 90

  4. Composite endpoint of mean score in PSI, Stroop Color-Word Test, Color Trails Test, Digit Span, Early Reha BI, Finger Tapping Test, MMSE, Hospital Anxiety and Depression Scale, GOS-E

    Time frame: Day 180

  5. Mortality

    Time frame: Day 180

07

Study locations

1 site
  • Prince of Wales Hospital
    Hong Kong, Hong Kong
08

References and documents

Publications

  • Poon W, Matula C, Vos PE, Muresanu DF, von Steinbuchel N, von Wild K, Homberg V, Wang E, Lee TMC, Strilciuc S, Vester JC. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020 Feb;41(2):281-293. doi: 10.1007/s10072-019-04053-5. Epub 2019 Sep 7. Erratum In: Neurol Sci. 2020 Mar;41(3):733. doi: 10.1007/s10072-019-04149-y. PubMed 31494820 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2012
First posted
May 25, 2012
Start
Sep 2013
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01606111
Lead sponsor
Ever Neuro Pharma GmbH
Responsible party
Sponsor
First posted
May 25, 2012
Start date
Sep 2013
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Feb 25, 2020

Study contacts

Wai S Poon, Prof.
principal investigator · Prince of Wales Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cerebrolysin

Start the discussion